Abstract：
:Gemcitabine, a novel nucleoside analog, shows reproducible response rates of 20% and above in single-agent studies in non-small cell lung cancer. In the phase II studies reported, chemotherapy-naive patients received gemcitabine (starting doses, 800 to 1,250 mg/ m2) as a single agent on days 1, 8, and 15 of a 28-day cycle. In three large studies of 82, 84, and 161 patients, response rates were 22.5%, 20%, and 21.8%, respectively. The median duration of response in these studies was 8.1, 12.7, and 7.6 months, respectively. The median length of survival for all patients (responders and non-responders) was 8.1, 9.2, and 9.4 months, respectively. Three trials in Japan involving 206 patients produced response rates of 16.3%, 26.0%, and 20.9%. A US phase I/II study of gemcitabine at doses of 1,000 to 2,800 mg/ m2 recorded an overall response rate of 26% in a population of mainly stage IV (87%) patients. Responses were seen across disease stages and histologic subtypes in performance status 0, 1, and 2 patients and in the elderly. Gemcitabine produced marked benefit (lasting 2 to 5 months) in a number of disease-related symptoms, most notably cough, hemoptysis, and dyspnea. Improvements in performance status were seen in 52% of patients receiving gemcitabine. Gemcitabine was well tolerated with few of the side effects normally associated with cytotoxic drugs.
journal_name
Semin Oncoljournal_title
Seminars in oncologyauthors
Le Chevalier Tsubject
Has Abstractpub_date
1996-10-01 00:00:00pages
36-42issue
5 Suppl 10eissn
0093-7754issn
1532-8708journal_volume
23pub_type
杂志文章,评审abstract：:The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant chemotherapy trials i...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：2000-06-01 00:00:00
abstract：:Developments in the treatment of extensive small cell lung cancer have proven effective in palliative management but have not yielded improvements in the cure rate for this disease. Strategies involving dose escalation of chemotherapy, including de novo and late intensification dose escalation and dose escalation with...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1992-12-01 00:00:00
abstract：:Multitargeted antifolate (MTA, LY231514) is a novel antifolate antimetabolite, with antitumor activity via inhibition of thymidylate synthase, glycinamide formyl transferase, and dihydrofolate reductase. Three dosing schedules have been investigated in the phase I setting: daily x5 every 21 days, weekly x4 every 42 da...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1999-04-01 00:00:00
abstract：:The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1016/s0093-7754(01)90276-3
更新日期：2001-10-01 00:00:00
abstract：:One of the new agents intensively studied in the last decade for the treatment of metastatic breast cancer is vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France). This vinca alkaloid produces response rates comparable to other single agents in women with m...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1995-04-01 00:00:00
abstract：:Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...
journal_title：Seminars in oncology
pub_type： 杂志文章,多中心研究,评审
doi：10.1053/j.seminoncol.2017.01.001
更新日期：2017-02-01 00:00:00
abstract：:Although more common in developing countries, over 11,000 deaths will occur in the United States from head and neck cancer in 2004. Squamous cell carcinomas account for the vast majority of cases in the United States and the majority of these are related to exposure to tobacco and alcohol. Newer data suggest a genetic...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2004.09.013
更新日期：2004-12-01 00:00:00
abstract：:CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible. ...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1985-03-01 00:00:00
abstract：:Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recen...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1992-12-01 00:00:00
abstract：:Medulloblastoma (MB) is the most common malignant brain tumor of childhood, yet it makes up only 1% of adult brain tumors. MB is uniquely sensitive to chemotherapy and radiation, but successful surgical resection continues to be an important component of therapeutic success. Progress in the treatment of MB has occurre...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2004.07.009
更新日期：2004-10-01 00:00:00
abstract：:It is well known that African American men are more likely to be diagnosed with metastatic prostate cancer than White men. Racial variation in the use of prostate cancer early detection modalities (ie, digital rectal examination [DRE] and prostate-specific antigen [PSA] testing) has been suggested as a major reason fo...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1999-08-01 00:00:00
abstract：:Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecu...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2014.12.004
更新日期：2015-02-01 00:00:00
abstract：:Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章
doi：
更新日期：1998-08-01 00:00:00
abstract：:Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first to study the effica...
journal_title：Seminars in oncology
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1053/j.seminoncol.2006.03.026
更新日期：2006-04-01 00:00:00
abstract：:The treatment of diffuse malignant pleural mesothelioma (MPM) is currently less than satisfactory. Survival statistics are best for the epithelial subtype and for tumors that can be completely removed by surgery. Radiotherapy provides no survival benefit and is used only to palliate symptoms or to prevent growth along...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/sonc.2002.30765
更新日期：2002-04-01 00:00:00
abstract：:In this review, we briefly summarize some of the key developments in nutritional epidemiology and cancer over the past two decades with a focus on the strengths and limitations of study designs and dietary assessment methods. We present the evidence on dietary fat, meat, fiber, antioxidant nutrients, and calcium in re...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2010.05.011
更新日期：2010-06-01 00:00:00
abstract：:The outcomes in young adults aged 20-39 with sarcoma tend to be inferior compared to those in children and adolescents. There are differences in sarcoma histotype distribution with age, such that pediatric-type tumors predominate in the 20- to 25-year-old group while more adult-type sarcomas occur in those aged 35-39 ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2009.03.006
更新日期：2009-06-01 00:00:00
abstract：:Lymphoma and myeloma represent an increasingly important cause of morbidity and mortality in the older patient group. Studies to date, while limited, suggest that there may be differences in the underlying biology of the tumor cell of some lymphoid malignancies in younger versus older patients. Significant new data wi...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2003.12.030
更新日期：2004-04-01 00:00:00
abstract：:The mainstay of screening for breast cancer is the mammogram. There are several randomized control trials that demonstrate a significant decrease in breast cancer mortality when compared to women without screening mammography included in their care. Digital mammography has improved detection in the dense breast. With ...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2010.11.004
更新日期：2011-02-01 00:00:00
abstract：:A phase I study of frequently administered carboplatin with recombinant human granulocyte colony-stimulating factor (filgrastim) has been performed in patients with newly diagnosed epithelial ovarian cancer. Recombinant human granulocyte colony-stimulating factor was administered at a dose of 5 micrograms/kg/d for day...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章
doi：
更新日期：1994-10-01 00:00:00
abstract：:Breast cancer patients undergoing therapeutic regimens of high-dose chemotherapy (HDCT) with circulating progenitor cell support often develop anemia. As a general consideration in the transplantation setting, red blood cell transfusions are normally required in patients who have passed the myeloablative phase after H...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/sonc.2002.33529
更新日期：2002-06-01 00:00:00
abstract：:Over the past three decades conceptual approaches to breast cancer have led to improvements in locoregional therapy and early diagnosis. Systematic screening programs with mammography reduce disease-specific mortality by 25% to 30%, while many patients with early breast cancer receive optimal breast-conserving treatme...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1999-08-01 00:00:00
abstract：:Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, usually develops in a liver already suffering from chronic damages, often cirrhosis. There has been marked progress in the treatment of HCC. However, effective treatments are limited to patients with less advanced HCC. The detection of HCC at an...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：10.1053/j.seminoncol.2012.05.009
更新日期：2012-08-01 00:00:00
abstract：:Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA ...
journal_title：Seminars in oncology
pub_type： 临床试验,杂志文章
doi：10.1016/s0093-7754(01)90156-3
更新日期：2001-08-01 00:00:00
abstract：:A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1990-12-01 00:00:00
abstract：:The activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been documented in untreated and previously treated metastatic breast cancer, including both patients with anthracycline-resistant disease and those with extensive pretreatment. Such activity has prompted investigations of...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1996-02-01 00:00:00
abstract：:Surgery is the major curative treatment modality for patients with malignant disease. However, surgery also plays an important role in supportive and palliative care of cancer patients. In settings in which maintaining quality of life rather than prolongation of survival is the major goal of treatment, the potential m...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1995-04-01 00:00:00
abstract：:Investigators representing all major melanoma research areas present an overview of the most important challenges for the field. Four major research areas are covered plus the training of new investigators. For each area we first describe the present status, its strengths and weaknesses, and then outline specific reco...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：10.1053/j.seminoncol.2007.09.004
更新日期：2007-12-01 00:00:00
abstract：:Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort...
journal_title：Seminars in oncology
pub_type： 杂志文章,评审
doi：
更新日期：1991-04-01 00:00:00
abstract：:Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor family, which produces factors that are considered to be important mediators of cell growth. Overexpression of HER2, which occurs in approximately 25% to 30% of human breast cancers, has fostered considerable interest i...
journal_title：Seminars in oncology
pub_type： 杂志文章
doi：
更新日期：1999-08-01 00:00:00
